Theresia Santi

Dr. Theresia Santi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
Theresia SantiTheresia Santi
Theresia Santi
VSVeli Sungono
Veli Sungono
LKLina Kamarga
Lina Kamarga
BSBaringin De Samakto
Baringin De Samakto
FHFerry Hidayat
Ferry Hidayat
JJJuandy Jo
Juandy Jo
Purpose: This study was performed to investigate humoral immune response and adverse events upon the heterologous prime-boost with a single dose of the mRNA-1273 vaccine among fully CoronaVac-vaccinated, infection-naive healthcare workers in Indonesia. Materials and Methods: One hundred twenty-five eligible healthcare workers were recruited from one hospital for this prospective cohort study. Blood collection was conducted twice, i.e., on 7 days before and 28 days after the booster vaccination. The titer of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies was quantified accordingly. The post-vaccination adverse event was recorded for both CoronaVac and mRNA-1273 vaccinations. Any breakthrough infection was monitored during the follow-up period. Wilcoxon matched-pairs signed rank test was used to test differences between groups. Results: A significant increase was observed in the titer of anti-SARS-CoV-2 RBD antibodies upon receiving the mRNA-1273 booster (geometric mean titers of 65.57 and 47,445 U/mL in pre and post-booster, respectively), supporting the argument to use heterologous prime-boost vaccination to improve the protection against COVID-19 in a high-risk population. The mRNA-1273 vaccine, however, caused a higher frequency of adverse events than the CoronaVac vaccine. Nonetheless, the adverse events were considered minor medical events and temporary as all subjects were not hospitalized and fully recovered. Of note, no breakthrough infection was observed during the follow-up to 12 weeks post-booster. Conclusion: The heterologous prime-boost vaccination of healthcare workers with a single dose of the mRNA-1273 vaccine generated a significant elevation in humoral immune response towards RBD of SARS-CoV-2 and was associated with a higher frequency, but minor and transient, adverse events.

1 January 2023 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
Theresia SantiTheresia Santi
Theresia Santi
BHBadriul Hegar
Badriul Hegar
ZMZakiudin Munasir
Zakiudin Munasir
APAri Prayitno
Ari Prayitno
RWRetno Asti Werdhani
Retno Asti Werdhani
Yvan VandenplasYvan Vandenplas
Yvan Vandenplas
Santi T, et al. Clin Exp Vaccine Res. 2023 Jul;12(3):240-248. https://doi.org/10.7774/cevr.2023.12.3.240

1 December 2022 in Infection & Chemotherapy
Verified
Journal Article
Open access
Theresia SantiTheresia Santi
Theresia Santi
LKLina Kamarga
Lina Kamarga
BSBaringin De Samakto
Baringin De Samakto
JJJuandy Jo
Juandy Jo
It remains unknown whether the Indonesian healthcare workers (HCWs) who had received two doses of CoronaVac vaccine and one dose of mRNA-1273 booster could be protected during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron wave. In total, 125 infection-naive and 10 previously infected HCWs were recruited. The mRNA-1273 booster substantially increased titer of anti-SARS-CoV-2 spike protein receptor-binding domain antibodies. However, the monitoring revealed that 34 out of 125 infection-naive (27.2%) and 3 out of 10 previously infected HCWs (30.0%) were infected during the Omicron wave. All infected HCWs were either asymptomatic or having mild coronavirus disease 2019 (COVID-19) and subsequently fully recovered, supporting the heterologous prime-boost strategy against COVID-19.

1 October 2021
Verified
Journal Article
Closed access
Theresia SantiTheresia Santi
Theresia Santi
BSBaringin De Samakto
Baringin De Samakto
LKLina Kamarga
Lina Kamarga
FHFeronica Kusuma Hidayat
Feronica Kusuma Hidayat
FHFerry Hidayat
Ferry Hidayat

21 November 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
Theresia SantiTheresia Santi
Theresia Santi
RRRidwansyah Ridwansyah
Ridwansyah Ridwansyah
VSVeli Sungono
Veli Sungono
NWNatalia Widjaya
Natalia Widjaya
KEKeinata Nabila Euqenekim
Keinata Nabila Euqenekim
JJJuandy Jo
Juandy Jo
Background/Objectives: In the absence of specific antiviral therapy for dengue viral infection, vaccination remains the most effective preventive measure. Two dengue vaccines have been licensed in Indonesia; however, concerns regarding vaccine hesitancy persist. This study aimed to assess dengue vaccine hesitancy among Indonesian office workers, comprising healthcare and non-healthcare workers. Methods: A cross-sectional study with an online survey was conducted between February 1 and April 30, 2025. Eligible participants were adults (≥18 years) employed in office-based settings, including healthcare facilities. Questionnaires were disseminated through company management teams and included 37 items on demographic characteristics, vaccination intentions, and underlying motivations. Data were analyzed to identify determinants of vaccine hesitancy. Results: A total of 377 respondents participated, the majority of whom were from West Java (335; 88.9%). One-third of respondents reported uncertainty regarding dengue vaccination (33.4% “not sure”), which was paralleled by hesitancy to pay for vaccination (43.2% “not sure”). Multivariable logistic regression analysis identified five significant determinants of vaccine hesitancy, with willingness-to-pay emerging as the strongest factor (β coefficient = 2.024; OR = 7.57; 95% CI = 4.06–14.10; p-value < 0.01). Conclusions: Approximately one-third of the surveyed Indonesian office workers exhibited hesitancy toward dengue vaccination. Willingness-to-pay was the most influential determinant of vaccine acceptance. Targeted strategies to address financial concerns and improve confidence in dengue vaccination are essential for strengthening workforce protection and national preparedness against dengue outbreaks.

27 February 2026 in Paediatrica Indonesiana
Verified
Journal Article
Open access
NDNaomi Esthernita F. Dewanto
Naomi Esthernita F. Dewanto
Theresia SantiTheresia Santi
Theresia Santi
ZSZaneth Sugiri
Zaneth Sugiri
NNNancy Napitupulu
Nancy Napitupulu
JJJuandy Jo
Juandy Jo
Background Previous studies have shown a 'tropical paradox' in Indonesia, where despite being a tropical country with abundant sunlight, a widespread vitamin D inadequacy is observed in various populations. This paradox extends to Indonesian children, who predominantly exhibit low vitamin D levels, yet research specifically investigating vitamin D status in the newborn remains notably limited. Objective To determine the prevalence of low level of vitamin D and elucidate its correlation with the conditions of newborns in Jakarta, Indonesia. Methods This retrospective study analyzed data from newborns undergoing assessment at Siloam Hospital Kebon Jeruk, Jakarta, from June 2022 to May 2024. We collected the following data: newborn’s vitamin D level, demographic and clinical characteristics, as well as available maternal data. Serum 25-hydroxyvitamin D [25(OH)D] levels between < 20, 20–29.9 and ≥ 30 ng/mL were classified as deficient, insufficient, and sufficient, respectively. Statistical analyses were used to compare baseline characteristics and outcomes based on vitamin D status. Results Of the 243 newborns studied, 70.4% were classified as vitamin D deficient, 22.2% as insufficient, and 7.4% as sufficient. Subjects’ median vitamin D level was 15.7 (range 1.2 – 57.1) ng/mL. No significant difference in vitamin D levels was observed between male and female newborns (p=0.190) and between newborns with birthweight < 2,500 and the ones with birth weight ≥2,500 grams (p=0.794). Vitamin D levels were not significantly different between healthy and sick newborns (p=0.537). Maternal vitamin D status was available for only a small proportion (15.6%) of mothers, highlighting the need for further investigation into maternal-newborn vitamin D status. Conclusion Although a high prevalence of newborn with vitamin D deficiency was observed in our study participants, no significant difference in vitamin D levels was observed between healthy and sick newborns. No correlation was observed between sex or birth weight, and vitamin D levels as well. Future inquiries should explore maternal vitamin D status in greater detail and assess the prolonged health consequences of hypovitaminosis D in newborns.